Severe anaphylactic reaction to infliximab: successful treatment with adalimumab – report of a case

Severe anaphylactic reaction to infliximab: successful treatment with adalimumab – report of a case

Treatment with the anti-tumour necrosis factor alpha chimeric monoclonal antibody infliximab is highly effective in the treatment of refractory and fistulising Crohn's disease. Infliximab has been tolerated well, with minimal and short-lived adverse effects. The likelihood of severe reactions t...

Full description

Saved in:
Bibliographic Details
Published in:European journal of gastroenterology & hepatology Vol. 16; no. 6; pp. 627 - 630
Main Authors: Stallmach, Andreas, Giese, Thomas, Schmidt, Carsten, Meuer, Stefan C, Zeuzem, Stefan S
Format: Journal Article
Language:English
Published: Hagerstown, MD Lippincott Williams & Wilkins, Inc 01-06-2004
Lippincott Williams & Wilkins
Subjects:
Adalimumab
Adult
Anaphylaxis - chemically induced
Anaphylaxis - drug therapy
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Biological and medical sciences
Crohn Disease - drug therapy
Female
Gastroenterology. Liver. Pancreas. Abdomen
Gastrointestinal Agents - adverse effects
Humans
Infliximab
Medical sciences
Case study
anti-tumour necrosis factor alpha
Treatment
Infliximab
Antibody
Critically ill
Gastroenterology
Adalimumab
Severe
Reaction
Tumor necrosis factor α
mucosal healing
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment with the anti-tumour necrosis factor alpha chimeric monoclonal antibody infliximab is highly effective in the treatment of refractory and fistulising Crohn's disease. Infliximab has been tolerated well, with minimal and short-lived adverse effects. The likelihood of severe reactions to infliximab, such as acute and delayed hypersensitivity infusion reactions, is small; nevertheless, if they do occur, they are life-threatening. We report a case of an anaphylaxis-like reaction in a 22-year-old female with long-standing Crohn's disease. The patient was treated successfully with adalimumab, a fully human anti-tumour necrosis factor alpha monoclonal antibody. Follow-up demonstrated mucosal healing and normalisation of elevated pro-inflammatory cytokine transcripts.
ISSN:0954-691X
1473-5687
DOI:10.1097/00042737-200406000-00018